Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
On November 13, 2026, Silexion Therapeutics Corp
issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2026. A copy of the
press release is furnished as Exhibit 99.1 hereto and is incorporated by reference into this Item 2.02.
The information contained in this Item 2.02 and
Exhibit 99.1 hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor will such information
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as may
be expressly set forth by specific reference in such filing.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Exhibit 99.1

Silexion Therapeutics
Reports Third Quarter 2026 Financial Results and
Provides Business
Update
First patient dosed in the Phase 2/3 clinical
trial of SIL204 in locally advanced pancreatic cancer at
Tel Aviv Sourasky Medical Center, moving SIL204 into active patient treatment
New translational data expanded SIL204’s
profile, including a coordinated immune-sensitization
signature across four KRAS mutations and a native lipoprotein-mediated uptake mechanism
that supports
systemic administration
Third quarter financings increased cash and
cash equivalents to $4.8 million and shareholders’ equity to
$3.0 million as of September 30, 2026
Grand Cayman, Cayman Islands, Nov. 13, 2026 -- Silexion Therapeutics
Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference
(RNAi) therapies for KRAS-driven cancers, today announced financial results for the three-month and nine-month periods ended September
30, 2026, and provided a business update.
Ilan Hadar, Chairman and Chief Executive Officer of Silexion, commented:
“In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first
clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September. At the same time, our laboratory
work continued to strengthen the case for SIL204, with new data suggesting it may help the immune system recognize cancer cells, and showing
that it uses natural carriers in the blood to enter cancer cells. Our focus now is on enrolling the first group of patients and bringing
more hospitals in Israel and Germany into the trial.”
Mirit Horenshtein Hadar, Chief Financial Officer of Silexion, added:
“During the third quarter, we completed a public offering and a warrant inducement transaction and continued sales under our at-the-market
facility, increasing our cash and cash equivalents to $4.8 million and shareholders’ equity to approximately $3.0 million as of
September 30, 2026. This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll
patients in the Phase 2/3 trial.”
Recent Milestones & Business Highlights
First Patient Dosed in Phase 2/3 Clinical Trial of SIL204:
On July 29, 2026, Silexion initiated its Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer (“LAPC”)
at Tel Aviv Sourasky Medical Center (“TASMC” or “Ichilov”), and on September 30, 2026, announced that the first
patient worldwide had been dosed at TASMC. The prospective, randomized, controlled, multinational, open-label Phase 2/3 study is evaluating
SIL204 in combination with standard-of-care chemotherapy, versus chemotherapy alone, in newly diagnosed, treatment-naïve patients
with unresectable Stage 3 LAPC whose tumors harbor a confirmed KRAS mutation. SIL204 is administered via a dual-route regimen combining
direct EUS-guided intratumoral delivery to the primary tumor with subcutaneous injections designed to provide systemic exposure. The
study is structured as an initial safety run-in cohort of approximately 18 patients, followed by expansion into a randomized cohort of
approximately 166 patients.
Clinical Site Expansion in Israel and Germany: In Israel, following
the approval of the Israeli Ministry of Health, TASMC was activated as the trial’s first clinical site in July 2026, and the first
patient was dosed there on September 30, 2026. Additional Israeli oncology centers, alongside leading academic medical institutions in
Germany, are progressing through site activation and are expected to join the trial in the coming months.
Expanded Translational Profile of SIL204: In August 2026, Silexion
reported preclinical findings showing statistically significant upregulation of FAS (CD95), an immune “death receptor,” and
downregulation of HLA-G, an established immune checkpoint, in human KRAS-mutant pancreatic and non-small cell lung cancer cell lines.
Together with the MHC-I upregulation reported in May 2026, the findings support a coordinated immune-sensitization signature across three
immune pathways and four KRAS mutations (G12D, G12V, G12C and G12R), reinforcing the scientific rationale for combining SIL204 with anti-PD-(L)1
checkpoint inhibitor therapies. In September 2026, the Company reported that SIL204 uses naturally circulating lipoproteins to enter cancer
cells and silence mutant KRAS without synthetic transfection reagents or artificial carriers, supporting the systemic administration of
SIL204. Pharmacokinetic, cellular uptake kinetics and biodistribution studies are ongoing.
Financing Activities: During the third quarter, Silexion completed
a registered public offering in August 2026 with gross proceeds of approximately $2.5 million and a warrant inducement transaction in
September 2026 with gross proceeds of approximately $0.84 million, and continued sales of ordinary shares under its at-the-market facility
for gross proceeds of approximately $1.9 million. Subsequent to quarter end, on November 10, 2026, the Company effected a 1-for-24 reverse
share split.
Financial Results for the Three Months Ended September 30, 2026
Research and development (“R&D”) expenses for the three
months ended September 30, 2026, were approximately $1.3 million, compared to approximately $2.2 million for the three months ended September
30, 2025, a decrease of 40.9%.
General and administrative (“G&A”) expenses for the
three months ended September 30, 2026, were approximately $1.4 million, compared to approximately $1.1 million for the three months ended
September 30, 2025, an increase of 27.3%.
Net loss for the three months ended September 30, 2026, was approximately
$2.5 million, compared to approximately $3.3 million for the three months ended September 30, 2025, a decrease of 24.2%.
Financial Results for the Nine Months Ended September 30, 2026
R&D expenses for the nine months ended September 30, 2026, were
approximately $4.9 million, compared to approximately $3.8 million for the nine months ended September 30, 2025, an increase of 28.9%.
The increase related to the operational ramp-up for the Phase 2/3 clinical trial of SIL204.
G&A expenses for the nine months ended September 30, 2026, were
approximately $4.2 million, compared to approximately $3.5 million for the nine months ended September 30, 2025, an increase of 20.0%.
Net loss for the nine months ended September 30, 2026, was approximately
$8.8 million, compared to approximately $7.5 million for the nine months ended September 30, 2025, an increase of 17.3%. The increase
was mainly due to higher R&D expenses related to the Phase 2/3 clinical trial of SIL204.
Balance Sheet Highlights
| · | As of September 30, 2026, Silexion had cash and cash equivalents of $4.8 million, compared to $6.0 million as of December 31, 2025,
and $2.2 million as of June 30, 2026. |
| · | Total shareholders’ equity was $3.0 million as of September 30, 2026, compared to $2.6 million as of December 31, 2025. |
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused
biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have
the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a
Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy
alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3
clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further
developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the federal securities laws. All statements other than statements of historical fact contained in this communication are forward-looking
statements, including, for example, statements regarding the development of SIL204; the conduct, enrollment and timing of the ongoing
Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer, including enrollment of the safety run-in cohort and expansion
into a randomized cohort; the timing of activation of additional clinical trial sites in Israel and Germany and the potential expansion
of the trial into additional jurisdictions; the timing and results of ongoing translational, pharmacokinetic, cellular uptake and biodistribution
studies, and the potential to evaluate SIL204 in combination with anti-PD-(L)1 checkpoint inhibitor therapies; the potential therapeutic
benefits, mutation coverage, mechanism of action and clinical utility of SIL204 across KRAS-driven cancers; Silexion’s business
strategy and development plans; Silexion’s ability to raise additional capital and its future capital requirements, including through
its at-the-market facility, public and private offerings, warrant exercises, warrant inducement transactions and other financing arrangements;
the outcome of litigation; and Silexion’s ability to restore and maintain compliance with Nasdaq continued listing requirements.
These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”,
“might”, “plan”, “possible”, “project”, “strive”, “budget”, “forecast”,
“expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”,
“predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar
terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ
materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not
limited to: (i) the degree of success of Silexion’s ongoing and planned clinical trials, including the Phase 2/3 clinical trial
of SIL204, and the risk that early observations may not be predictive of later results; (ii) Silexion’s ability to enroll and treat
patients, and to complete the activation of additional clinical sites, on anticipated timelines; (iii) whether Silexion is able to successfully
execute upon its strategy and plans via its future operations, and maintain a positive financial position; (iv) the impact of the regulatory
environment and compliance complexities; (v) whether Silexion is able to develop future partnerships or other relationships with third
parties; (vi) Silexion’s future capital requirements and sources and uses of cash, and the potential impact on the Company’s
operations of any inability to secure such capital; (vii) the substantial doubt about the Company’s ability to continue as a going
concern described in Note 1(e) to the Company’s unaudited condensed consolidated financial statements for the three-month and nine-month
periods ended September 30, 2026; (viii) whether Silexion succeeds at maintaining its Nasdaq listing, including the determination of the
Nasdaq hearings panel, compliance with the shareholders’ equity and minimum bid price requirements, and any potential increase to
the market value of listed securities requirement; and (ix) other risks and uncertainties set forth in the documents filed by the Company
with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March
17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November
12, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based
on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak
only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes
in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com
Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except share and
per share data)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| ASSETS | |
| | | |
| | |
| CURRENT ASSETS: | |
| | | |
| | |
| Cash and cash equivalents | |
$ | 4,760 | | |
$ | 5,991 | |
| Restricted cash | |
| 28 | | |
| 27 | |
| Prepaid expenses | |
| 1,221 | | |
| 570 | |
| Other current assets | |
| 102 | | |
| 49 | |
| TOTAL CURRENT ASSETS | |
| 6,111 | | |
| 6,637 | |
| | |
| | | |
| | |
| NON-CURRENT ASSETS: | |
| | | |
| | |
| Restricted cash | |
| 61 | | |
| 57 | |
| Long-term deposit and other non-current assets | |
| 320 | | |
| 84 | |
| Property and equipment, net | |
| 21 | | |
| 25 | |
| Operating lease right-of-use asset | |
| 314 | | |
| 412 | |
| TOTAL NON-CURRENT ASSETS | |
| 716 | | |
| 578 | |
| | |
| | | |
| | |
| TOTAL ASSETS | |
$ | 6,827 | | |
$ | 7,215 | |
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(continued)
(U.S. dollars in thousands, except share and
per share data)
| | |
September 30, | | |
December 31, | |
| | |
2026 | | |
2025 | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| CURRENT LIABILITIES: | |
| | | |
| | |
| Trade payables | |
$ | 1,244 | | |
$ | 787 | |
| Current maturities of operating lease liability | |
| 196 | | |
| 182 | |
| Employee related obligations | |
| 460 | | |
| 879 | |
| Other account payable | |
| 1,781 | | |
| 910 | |
| Private warrants to purchase ordinary shares (including $* due to related party, as of September 30, 2026 and December 31, 2025) | |
| * | | |
| * | |
| TOTAL CURRENT LIABILITIES | |
| 3,681 | | |
| 2,758 | |
| | |
| | | |
| | |
| NON-CURRENT LIABILITIES: | |
| | | |
| | |
| Long-term operating lease liability | |
| 178 | | |
| 286 | |
| Related Party Promissory Note | |
| - | | |
| 1,568 | |
| TOTAL NON-CURRENT LIABILITIES | |
$ | 178 | | |
$ | 1,854 | |
| TOTAL LIABILITIES | |
$ | 3,859 | | |
$ | 4,612 | |
| | |
| | | |
| | |
| SHAREHOLDERS’ EQUITY: | |
| | | |
| | |
| Ordinary shares ($3.24 par value per share, 662,500 and 37,500 shares authorized as of September 30, 2026 and December 31, 2025, respectively; 603,055 and 13,028 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively) | |
| 1,954 | | |
| 42 | |
| Additional paid-in capital | |
| 64,997 | | |
| 57,727 | |
| Accumulated deficit | |
| (63,983 | ) | |
| (55,166 | ) |
| TOTAL SHAREHOLDERS’ EQUITY | |
$ | 2,968 | | |
$ | 2,603 | |
| | |
| | | |
| | |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | |
$ | 6,827 | | |
$ | 7,215 | |
All share amounts, and par value per share, reflect a 1-for-10 reverse
share split effected on May 28, 2026, and a 1-for-24 reverse share split effected on November 10, 2026, as described in Notes 1(d) and
13 to the Company’s condensed consolidated financial statements included in the Company’s quarterly report on Form 10-Q for
the quarter ended September 30, 2026.
* Represents an amount less than $1 thousand.
SILEXION THERAPEUTICS CORP
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
(U.S. dollars in thousands, except share and
per share data)
| | |
Nine months ended September 30, | | |
Three months ended September 30, | |
| | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| OPERATING EXPENSES: | |
| | | |
| | | |
| | | |
| | |
| Research and development (including $176 and $0 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $0 from related party for the three-month periods ended September 30, 2026 and 2025) | |
$ | 4,868 | | |
$ | 3,765 | | |
$ | 1,286 | | |
$ | 2,157 | |
| General and administrative (including $298 and $96 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $16 and $38 from related party for the three-month periods ended September 30, 2026 and 2025, respectively) | |
| 4,245 | | |
| 3,461 | | |
| 1,398 | | |
| 1,135 | |
| TOTAL OPERATING EXPENSES | |
| 9,113 | | |
| 7,226 | | |
| 2,684 | | |
| 3,292 | |
| OPERATING LOSS | |
| 9,113 | | |
| 7,226 | | |
| 2,684 | | |
| 3,292 | |
| Financial expenses (income), net (including $(307) and $203 from related party for the nine-month periods ended September 30, 2026 and 2025, respectively, and $(138) and $(26) from related party for the three-month periods ended September 30, 2026 and 2025, respectively) | |
| (296 | ) | |
| 271 | | |
| (151 | ) | |
| (30 | ) |
| LOSS BEFORE INCOME TAX | |
$ | 8,817 | | |
$ | 7,497 | | |
$ | 2,533 | | |
$ | 3,262 | |
| INCOME TAX | |
| * | | |
| 3 | | |
| * | | |
| - | |
| NET LOSS | |
$ | 8,817 | | |
$ | 7,500 | | |
$ | 2,533 | | |
$ | 3,262 | |
| | |
| | | |
| | | |
| | | |
| | |
| LOSS PER SHARE, BASIC AND DILUTED | |
$ | 115.56 | | |
$ | 2,486.20 | | |
$ | 13.70 | | |
$ | 691.14 | |
| | |
| | | |
| | | |
| | | |
| | |
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE** | |
| 76,305 | | |
| 3,017 | | |
| 184,927 | | |
| 4,720 | |
* Represents an amount less than $1 thousand.
** All share and per share amounts reflect (for periods preceding
the relevant reverse share split, on a retroactive basis) the 1-for-10 reverse share split effected on May 28, 2026 and the 1-for-24 reverse
share split effected on November 10, 2026, as described in Notes 1(d) and 13 to the Company’s condensed consolidated financial statements
included in the Company’s quarterly report on Form 10-Q for the quarter ended September 30, 2026.